{"data": [{"news_url": "https://www.fool.com/investing/2020/10/19/how-should-investors-play-covid-19-stocks/", "image_url": "https://cdn.snapi.dev/images/v1/c/z/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f5674222fstethoscope-over-money-healthcare-costs-obamacare-gettyjpgw700opresize.jpg", "title": "How Should Investors Play COVID-19 Stocks?", "text": "Treatments, vaccines, or both?", "source_name": "The Motley Fool", "date": "Mon, 19 Oct 2020 15:02:00 -0400", "topics": [], "sentiment": "Neutral", "type": "Article", "tickers": ["LLY", "MRNA", "REGN"]}, {"news_url": "https://www.benzinga.com/general/biotech/20/10/17961560/moderna-nears-finish-line-for-enrollment-in-phase-3-coronavirus-vaccine-study", "image_url": "https://cdn.snapi.dev/images/v1/d/s/syringe-1884758-1920-72.jpg", "title": "Moderna Nears Finish Line For Enrollment In Phase 3 Coronavirus Vaccine Study", "text": "Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) is close to achieving 100% enrollment in its Phase 3 COVE study.\u00a0 What Happened: After seeing a slowdown in the enrollment rate in recent weeks, the pace of addition picked up in the recent week, according to statistics shared by the company on Twitter.", "source_name": "Benzinga", "date": "Mon, 19 Oct 2020 14:17:54 -0400", "topics": [], "sentiment": "Positive", "type": "Article", "tickers": ["MRNA"]}]}